US-based company Debut Biotechnology has unveiled “DermCeutical PNar”, a cosmetic active ingredient designed to visibly reduce hyperpigmentation and brighten the skin without causing irritation. The ingredient was developed using the company's proprietary technology platform, which combines AI, skin genomics and biotechnology, according to the San Diego-based biotech company. The aim is to treat dark spots and uneven skin tone without irritating the skin. According to Debut, the active ingredient is effective at a concentration of just 0.45 percent. It is positioned as an alternative to conventional skin-brightening ingredients such as kojic acid.

Less Melanin

According to Debut, the active ingredient targets the underlying biological causes of hyperpigmentation. To achieve this, the company developed an entirely new molecule. The ingredient inhibits certain enzymes, including tyrosinase, which are involved in the production of the skin pigment melanin. This can reduce melanin production before dark spots even develop. In a twelve-week study using the ingredient at a concentration of 0.45 percent, 97 percent of participants showed improvements in hyperpigmentation, while 88 percent experienced skin brightening, according to Debut. The ingredient is suitable for different skin tones and is reportedly well tolerated even by sensitive skin. Debut also points to the EU restriction on kojic acid, which came into effect in 2025 and limits its concentration in face and hand care products to a maximum of one percent.

New Molecules from the AI Lab

With this development, Debut is pursuing an approach that involves designing new molecules to target specific biological structures. Using AI and extensive skin biology data, the company identifies specific mechanisms of action and designs molecules tailored to them. “DermCeutical PNar” demonstrates that high efficacy and good skin tolerability can go hand in hand, explained Debut founder and CEO Joshua Britton. Hyperpigmentation is considered a widespread skin concern worldwide. In an international survey of 48,000 adults across 34 countries conducted in 2025, one in two respondents reported experiencing at least one form of hyperpigmentation.

Source: Debut